Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that the first patient received TLX101-Tx treatment in its IPAX BrIGHT phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE